H. Lundbeck Asedebart Phase II Data
Analysis based on 6 articles · First reported Jun 14, 2026 · Last updated Jun 15, 2026
The positive preliminary Phase II data for asedebart could significantly boost investor confidence in Lundbeck's drug development capabilities, potentially leading to an increase in its stock price. This development also highlights the potential for new therapeutic options in the rare endocrine disorder market, attracting attention to the biotechnology and pharmaceutical sectors.
Lundbeck announced positive preliminary Phase II Part A data for asedebart, an anti-ACTH monoclonal antibody, in adults with Cushing's disease (CD). The data, presented at ENDO 2026, showed urinary free cortisol (UFC) normalization in 7 out of 8 evaluable patients who completed individualized intravenous dose titration. Asedebart was generally well tolerated, with no new safety signals. This investigational drug aims to neutralize excess ACTH to reduce cortisol production, addressing a significant unmet medical need in CD. Asedebart has received Orphan Drug Designation in the European Union, the United States, and Japan for CD and congenital adrenal hyperplasia. Lundbeck plans to evaluate a subcutaneous formulation in Part B of the study.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard